will AI replace ophthalmologists?

The irreplaceable centre of your work is physical. You're cutting into eyes, managing postoperative complications, and making real-time surgical decisions that no algorithm can execute. Cataract surgery, glaucoma procedures, vitreoretinal work — these require hands, eyes, and the kind of judgment that comes from years of operating. A model can't hold a phacoemulsification probe.

Beyond surgery, your clinical reasoning is what separates diagnosis from data. You're not just reading a scan — you're integrating a patient's history, their risk tolerance, their other medications, and what you see when you look at their eye directly. Developing a treatment plan for a patient with advanced glaucoma and diabetes, for example, means weighing surgical risk against vision loss trajectory. That's not a pattern-matching problem. That's medicine.

The relationship side matters too. Educating a 70-year-old patient about why they need cataract surgery, managing their anxiety, getting their consent in a way they actually understand — that's yours. According to O*NET task data, 17 of your 18 core tasks sit at zero AI penetration. That's not a gap that's about to close. The physical and judgment-heavy nature of ophthalmic work is exactly why this role scores 73 out of 100 on the safety scale.

AI image analysis in ophthalmology sounds impressive in press releases. In practice, it has a narrower job than anyone admits. Tools like IDx-DR can flag diabetic retinopathy from retinal photos, but they can't tell you what to do about it. They can't examine the anterior segment, assess intraocular pressure by feel, or notice that a patient is flinching in a way that suggests their symptoms are worse than the scan shows.

Hallucination is a real risk when AI touches clinical documentation. If you use any AI drafting tool for medical records, the text it produces can contain plausible-sounding errors: wrong laterality, incorrect medication dosages, fabricated findings. In ophthalmology, a note that says "left eye" when you treated the right eye isn't a minor typo. It's a liability event. No tool audits itself.

There's also the accountability gap. AI tools have no medical licence. When something goes wrong after a procedure, the responsibility sits with you, not with whatever software flagged an anomaly or drafted a note. Regulators haven't resolved how AI-assisted decisions interact with physician liability, and until they do, every AI output in a clinical setting needs your eyes on it.

The one task where AI is genuinely useful today is documentation. Tools like Nuance DAX Copilot and Nabla can listen to your patient encounter and draft a structured clinical note in under a minute. For a busy clinic running 30 patients a day, that's real time back. The notes still need your review, but the blank-page problem disappears.

On the diagnostic side, FDA-cleared tools like IDx-DR (now rebranded as LumineticsCore) can autonomously screen for diabetic retinopathy from fundus photos without a physician reading the image in real time. This is useful in primary care settings and remote screening programs, not as a replacement for your assessment, but as a triage filter that catches patients who need to see you. Similarly, Zeiss and Heidelberg both have AI-assisted layers built into their OCT platforms that flag progression in glaucoma patients by comparing sequential scans automatically.

Research and literature tools like Semantic Scholar and Microsoft's Azure AI Search are being used to surface relevant clinical evidence faster, cutting down the time it takes to check whether a treatment protocol has updated evidence behind it. These aren't transforming clinical practice, but they reduce the background reading burden. The honest summary: AI handles note-taking and image flagging. Everything requiring a decision, a prescription, or a scalpel is still yours.

The biggest shift for most ophthalmologists using AI tools is at the ends of the day. The pre-clinic prep and post-clinic documentation that used to consume 45 to 90 minutes now takes less time. Notes get drafted faster. You spend more time reviewing them than writing them from scratch.

What hasn't changed is the shape of your clinical day. You're still moving room to room, doing slit lamp exams, checking pressures, reviewing scans with patients, and making surgical decisions. The ratio of face-time to admin has shifted slightly in favour of face-time, but it's not dramatic. If anything, the bigger time drain now is reviewing AI-generated outputs carefully enough to catch errors before they're signed. That review step is new and it takes focus.

Surgical scheduling, postoperative follow-up protocols, and anything requiring your signature — none of that has changed. The parts of the job that require your physical presence or your name on a document are the same as they were five years ago.

The BLS projects 4.3% growth for physicians and surgeons through 2034, which is roughly in line with the average for all occupations. For ophthalmologists specifically, that number is shaped by two things: an ageing population and a shortage of trained specialists. The U.S. has about 12,500 ophthalmologists serving a country where age-related eye disease — cataracts, macular degeneration, glaucoma — is growing fast as baby boomers move into their 70s and 80s.

AI exposure doesn't threaten that growth. It doesn't compress demand and it doesn't reduce the number of surgeries needed. If anything, AI screening tools like LumineticsCore are identifying more patients who need ophthalmic care, not fewer. A flagged diabetic retinopathy case in a primary care clinic becomes a referral to you. The pipeline gets longer, not shorter.

With only 300 annual openings and a speciality that takes over a decade to train for — four years of medical school, one year of internship, three years of residency, often a fellowship — supply isn't going to surge. There's no version of this where AI floods the market with new ophthalmologists. The credential barrier alone makes this one of the most protected specialities in medicine.

The AI exposure score for ophthalmologists is essentially zero today, and it's unlikely to move dramatically in the next five years. The tasks that would need to change are surgical execution and in-person clinical judgment. Robotic surgery platforms like the Zeiss ARTEVO and Alcon's NGENUITY system are adding AI-assisted visualisation layers, but the surgeon is still operating. Full autonomous ophthalmic surgery is a research problem, not a near-term deployment.

To genuinely threaten this role, you'd need AI that can perform microsurgery with sub-millimetre precision, adapt in real time to unexpected intraoperative findings, manage complications, and carry legal accountability for outcomes. None of those exist. The more realistic 10-year trajectory is that AI handles more of the screening and monitoring work, which frees you to focus on the complex cases. That's a workload shift, not a displacement.

The safest thing you can do is go deeper on surgical complexity. Subspecialty training in vitreoretinal surgery, oculoplastics, or corneal transplantation puts you in the part of the field furthest from any realistic automation. These procedures are technically demanding, low-volume, and high-stakes. No one is building an autonomous vitreoretinal robot for clinical use in the next decade.

Get comfortable using documentation tools, but stay rigorous about reviewing their output. The ophthalmologists who get into trouble won't be the ones who avoided AI — they'll be the ones who signed notes they didn't read. Build the habit of treating every AI-drafted note as a first draft that needs your clinical eye, not a finished product.

If you're earlier in your career, pay attention to how AI screening tools are changing the referral pipeline. Understanding how primary care is using autonomous screening means you can position yourself to capture those referrals, work with health systems that are deploying these tools, and consult on how screening protocols should be designed. That's a professional edge that compounds over time. The shortage of trained ophthalmologists is real and isn't going away. Your biggest career risk isn't AI. It's burnout from a high-volume, under-resourced system — which is a different problem with different solutions.